Thymosin Beta-4, often abbreviated Tβ4 or TB4, is a naturally occurring peptide found in many tissues throughout the body. It is composed of 43 amino acids and is involved in several cellular processes related to tissue repair, cell migration, inflammation control, angiogenesis, and wound healing.
Thymosin Beta-4 is one of the major intracellular actin-sequestering peptides, meaning it binds to actin, a key structural protein involved in cell movement, shape, and repair. Because of these properties, Thymosin Beta-4 has been studied for wound healing, corneal injury, dry eye disease, cardiac repair, tissue regeneration, and inflammatory conditions.
In the wellness and peptide-therapy space, Thymosin Beta-4 is sometimes discussed alongside TB-500. However, TB-500 is typically marketed as a synthetic fragment or derivative related to Thymosin Beta-4 and should not automatically be considered identical to pharmaceutical-grade full-length Thymosin Beta-4 used in clinical research.
Thymosin Beta-4 plays an important role in actin regulation, which is essential for cell movement, wound repair, and tissue remodeling.
Potential mechanisms include:
Through these pathways, Thymosin Beta-4 has been studied as a regenerative peptide with potential applications in skin wounds, corneal injuries, cardiac injury, and inflammatory tissue damage.
Published research suggests Thymosin Beta-4 may have several biologic effects, although many uses remain investigational.
Potential benefits may include:
It is important to note that many of these potential benefits are based on preclinical research, animal studies, or limited human trials. Thymosin Beta-4 is not FDA-approved for general tissue repair, injury recovery, anti-aging, athletic performance, or regenerative medicine use.
Because Thymosin Beta-4 is not FDA-approved as a marketed drug in the United States, its complete safety profile has not been fully established.
Potential risks may include:
Because Thymosin Beta-4 may influence cell migration, tissue remodeling, angiogenesis, and inflammatory pathways, caution is appropriate in patients with malignancy, proliferative disorders, or unexplained masses.
Thymosin Beta-4 should generally be avoided or used only with extreme caution in individuals with:
Patients considering Thymosin Beta-4 should be evaluated by a qualified healthcare provider, particularly if they have cancer history, autoimmune disease, diabetes, impaired wound healing, or are taking immunosuppressive medications.
Thymosin Beta-4 is not FDA-approved for any medical indication in the United States.
It is not FDA-approved for:
An ophthalmic formulation of Thymosin Beta-4, known as RGN-259, has been studied in clinical trials for dry eye disease and neurotrophic keratopathy, but it has not received FDA marketing approval as of July 2026.
Human Studies
Human research on Thymosin Beta-4 has focused primarily on ophthalmic uses, especially dry eye disease and corneal healing.
A phase 2 clinical trial of topical Thymosin Beta-4 eye drops reported improvement in signs and symptoms of severe dry eye disease. Additional ophthalmic research has evaluated RGN-259, a Thymosin Beta-4 ophthalmic solution, for dry eye and neurotrophic keratopathy.
Human evidence outside ophthalmology remains limited. While Thymosin Beta-4 has been explored for wound healing and tissue repair, many proposed systemic uses rely primarily on animal or preclinical data rather than large, controlled human trials.
Animal & Preclinical Studies
Animal and laboratory studies suggest Thymosin Beta-4 may:
These findings support biologic plausibility but do not establish safety or efficacy for common off-label uses in humans.
Human Studies
Animal & Preclinical Studies
Review Articles
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
Thymosin Beta-4 is not FDA-approved for any medical indication in the United States. Any clinical use may be considered investigational or off-label depending on context. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# Thymosin Alpha-1 (Tα1)